Introducing Dr Stephen Hahn, the FDA's new Commissioner

fda-blog-700

By Dr Nicola Davies

The US Food and Drug Administration has started 2020 under the leadership of Dr Stephen Hahn, their new Commissioner. Dr Hahn’s role was confirmed by the US Senate with a 72-18 vote on December 12, 2019.1

Dr Hahn was sworn in as the 24th FDA Commissioner on December 17, 2019.2 He has become the fourth FDA Commissioner in less than a year, replacing Acting Commissioner, Brett Giroir. He is the first permanent commissioner that has been appointed since Dr Scott Gottlieb’s unexpected resignation in April 2019. Prior to Brett Giroir’s reign, Norman Sharpless also served as an interim commissioner from April to November 2019.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical